Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report)’s share price traded up 4.5% on Monday . The stock traded as high as $3.95 and last traded at $3.91. 87,825 shares were traded during mid-day trading, a decline of 52% from the average session volume of 183,452 shares. The stock had previously closed at $3.74.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. TheStreet upgraded shares of Eton Pharmaceuticals from a “d” rating to a “c-” rating in a report on Wednesday, August 16th. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, August 11th.
Eton Pharmaceuticals Stock Performance
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings results on Thursday, August 10th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.27. Eton Pharmaceuticals had a negative net margin of 0.81% and a negative return on equity of 1.79%. The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $6.50 million. Analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.1 earnings per share for the current fiscal year.
Institutional Trading of Eton Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bailard Inc. bought a new stake in Eton Pharmaceuticals during the second quarter worth $44,000. Raymond James & Associates bought a new stake in Eton Pharmaceuticals during the first quarter worth $38,000. Stratos Wealth Partners LTD. bought a new stake in Eton Pharmaceuticals during the first quarter worth $355,000. Acuitas Investments LLC bought a new position in shares of Eton Pharmaceuticals in the first quarter valued at about $1,804,000. Finally, State Street Corp raised its position in shares of Eton Pharmaceuticals by 9.3% in the first quarter. State Street Corp now owns 91,603 shares of the company’s stock valued at $399,000 after purchasing an additional 7,831 shares during the period. 23.30% of the stock is owned by institutional investors.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning.
- Five stocks we like better than Eton Pharmaceuticals
- Best Restaurant Stocks to Invest in Now
- Amazon just gave us 3 reasons to expect fresh highs
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- McDonald’s bottoms, plus more good news for fast food stocks
- How to Invest in EV Charging Stations
- Is Apple a buy ahead of earnings?
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.